Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib PK in Hepatic Impairment
NCT02063230Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2014
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of selumetinib in solid tumor (4 arms), sponsored by AstraZeneca. Primary endpoints: AUC (0 to Infinity) of Total Selumetinib, Cmax of Total Selumetinib and 4 more. Started Mar 2014; status: completed.
02
Drugs
selumetinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02063230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02063230.